BioMarin Pharmaceutical Inc.NASDAQ: BMRN

BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A

· Issued by BioMarin Pharmaceutical Inc.

On 6ix: 6ix.com/news/biomarin-announces-publication-in-new-england-journal-of-medicine-of-one-year-results

Watch BioMarin Pharmaceutical's latest callBioMarin Pharmaceutical (NASDAQ:BMRN) Q2 2026 Earnings Call · Replay · Aug 6Read the transcript of BioMarin Pharmaceutical (NASDAQ:BMRN) Q2 2026 Earnings Call

New England Journal of Medicine Publishes Editorial: Prepare the Way for Hemophilia A Gene Therapy

Significantly Reduced Bleeding and Factor VIII Utilization Compared to Baseline Factor VIII Prophylactic Therapy

Mean Annualized Bleeding Rate (ABR) Reduced by 84% (p-value

BioMarin Pharmaceutical Inc. on 6ix

Story so far

Earlier from BioMarin Pharmaceutical

Later from BioMarin Pharmaceutical

All BioMarin Pharmaceutical news releases